Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer

Journal of Ovarian Research

Volumn 9, Issue 1, 2016, Pages

  Zhang, He ^a   Li, Jingchao ^b   Hu, Yong ^b   Shen, Mingwu ^b   Shi, Xiangyang ^b   Zhang, Guofu ^a  

^a FUDAN UNIVERSITY   (China)

^b DONGHUA UNIVERSITY   (China)

Author keywords

Folic acid; Iron oxide nanoparticles; Magnetic resonance imaging; Ovarian cancer; Targeting

Indexed keywords

FOLATE RECEPTOR; FOLIC ACID TARGETED IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; FOLIC ACID; MAGNETITE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMORTALIZED OVARY CELL LINE; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; SKOV 3 CELL LINE; SYNTHESIS; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; EARLY CANCER DIAGNOSIS; INTRAVENOUS DRUG ADMINISTRATION; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; EARLY DETECTION OF CANCER; FEMALE; FOLIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS;

EID: 85007578801     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/s13048-016-0230-2     Document Type: Article

References (45)

1. Moyle P, Addley HC, Sala E. Radiological staging of ovarian carcinoma. Semin Ultrasound CT MR. 2010;31:388-98.
2. Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol. 2012;24:8-13.
3. Ozols R, Bookman M, Connolly D, et al. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19-24.
4. Vencken P, Kriege M, Hoogwerf D, Beugelink S, van der Burg M, Hooning M. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22:1346-52.
5. Morgan R, Alvarez R, Armstrong D, et al. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012;10:1339-49.
6. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29:4662-8.
7. Yamashita Y, Torashima M, Hatanaka Y, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology. 1995;194:557-65.
8. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology. 2000;214:39-46.
9. Zhang H, Zhang G-F, He Z-Y, Li Z-Y, Zhang G-X. Prospective evaluation of 3T MRI findings for primary adnexal lesions and comparison with the final histological diagnosis. Arch Gynecol Obstet. 2014;289:357-64.
10. Yang H, Zhuang Y, Sun Y, et al. Targeted dual-contrast T1-and T2-weighted magnetic resonance imaging of tumors using multifunctional gadoliniumlabeled superparamagnetic iron oxide nanoparticles. Biomaterials. 2011;32: 4584-93.
11. Wen S, Li K, Cai H, et al. Multifunctional dendrimer-entrapped gold nanoparticles for dual mode CT/MR imaging applications. Biomaterials. 2013;34:1570-80.
12. Shi X, Wang SH, Swanson SD, et al. Dendrimer-functionalized shellcrosslinked iron oxide nanoparticles for in-vivo magnetic resonance imaging of tumors. Adv Mater. 2008;20:1671-8.
13. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater. 2007;19:3163-6.
14. Zhang H, Li J, Sun W, Hu Y, Zhang G, Shen M, Shi X. Hyaluronic acidmodified magnetic iron oxide nanoparticles for MR imaging of surgically induced endometriosis model in rats. PLoS One. 2014;9:e94718.
15. Shao HMC, Issadore D, Liong M, Yoon TJ, Weissleder R, Lee H. Magnetic nanoparticles and microNMR for diagnostic applications. Theranostics. 2012;2:55-65.
16. Hayashi KNM, Sakamoto W, Yogo T, Miki H, Ozaki S, Abe M, Matsumoto T, Ishimura K. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics. 2013;3:366-76.
17. Lee N, Choi Y, Lee Y, et al. Water-dispersible ferrimagnetic iron oxide nanocubes with extremely high r2 relaxivity for highly sensitive in vivo MRI of tumors. Nano Lett. 2012;12:3127-31.
18. Xu C, Sun S. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Dalton Trans. 2009;29:5583-91.
19. Sega E, Low P. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008;27:655-64.
20. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13:256-62.
21. Li J, Zheng L, Cai H, et al. Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR imaging. Biomaterials. 2013;34:8382-92.
22. Chen Q, Li K, Wen S, et al. Targeted CT/MR dual mode imaging of tumors using multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials. 2013;34:5200-9.
23. Li J, Hu Y, Yang J, et al. Facile synthesis of folic acid-functionalized iron oxide nanoparticles with ultrahigh relaxivity for targeted tumor MR imaging. J Mater Chem B. 2015;3:5720-30.
24. Satpathy M, Wang L, Zielinski R, et al. Active targeting using HER-2-affibodyconjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small. 2014;10:544-55.
25. Hensley NAR HH, O'Brien SW, Bickel LE, Fang X, Sam L, Connolly DC. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia. 2012;14:451-62.
26. Zhang X, Chen J, Kang Y, et al. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma. Int J Pharm. 2013;453:498-505.
27. X-y Z. Chen J, Zheng Y-f, et al. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 2009;69:6506-14.
28. Gallo J, Long NJ, Aboagye EO. Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer. Chem Soc Rev. 2013;42:7816-33.
29. Berry CC, Wells S, Charles S, Aitchison G, Curtis ASG. Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. Biomaterials. 2004;25:5405-13.
30. Larsen EKU, Nielsen T, Wittenborn T, et al. Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano. 2009;3:1947-51.
31. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31:6317-24.
32. Turcheniuk K, Tarasevych AV, Kukhar VP, Boukherroub R, Szunerits S. Recent advances in surface chemistry strategies for the fabrication of functional iron oxide based magnetic nanoparticles. Nanoscale. 2013;5:10729-52.
33. Hao R, Yu J, Ge Z, et al. Developing Fe3O4 nanoparticles into an efficient multimodality imaging and therapeutic probe. Nanoscale. 2013;5:11954-63.
34. Yen SKPP, Selvan ST. Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery. Theranostics. 2013;3:986-1003.
35. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
36. Li J, He Y, Sun W, et al. Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials. 2014;35:3666-77.
37. Li J, Zheng L, Cai H, et al. Facile one-pot synthesis of Fe3O4@Au composite nanoparticles for dual-mode MR/CT imaging applications. ACS Appl Mater Interfaces. 2013;5:10357-66.
38. Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007;67:8156-63.
39. Jiang G, Park K, Kim J, et al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers. 2008;89:635-42.
40. Cai H, An X, Cui J, et al. Facile hydrothermal synthesis and surface functionalization of polyethyleneimine-coated iron oxide nanoparticles for biomedical applications. ACS Appl Mater Interfaces. 2013;5:1722-31.
41. Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631-42.
42. Zhang J, Chen X, Shi G, et al. Establishment of a new representative model of human ovarian cancer in mice. J Ovarian Res. 2013;6:9.
43. Quinn B, Xiao F, Bickel L, et al. Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res. 2010;3:24.
44. Bankert RBB-IS, Odunsi K, Shultz LD, Kelleher Jr RJ, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011;6:e24420.
45. Hensley H, Quinn BA, Wolf RL, et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther. 2007;6:1717-25.